Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 104, 2015
Previous Article Next Article

Reaching beyond HIV/HCV: nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus

Author affiliations

Abstract

Drug repurposing or re-profiling has become an effective strategy to identify novel indications for already-approved drugs. In this study, peptidomimetic FDA-approved HIV/HCV inhibitors were explored for their potential to be repurposed for the inhibition of the replication of dengue (DENV) and chikungunya virus (CHIKV) by targeting the NS2B-NS3 and NSP2 protease, respectively. MM/GBSA-based binding free energy results put nelfinavir forward as a potential inhibitor of both dengue and chikungunya virus, which subsequently was further explored in a virus-cell-based assay for both viruses. Nelfinavir showed modest antiviral activity against CHIKV (EC50 = 14 ± 1 μM and a selectivity index of 1.6) and was slightly more active against DENV-2 (EC50 = 3.5 ± 0.4 μM and a selectivity index of 4.6). Even though the antiviral potency was limited, the fact that some activity was observed in these assays made it worthwhile exploring the potential and properties of nelfinavir as a stepping-stone compound: a more detailed computational analysis was performed to understand the binding mode, interaction, hydrogen bond distance, occupancy and minimum pharmacophoric features. The comprehensive data set that resulted from these analyses may prove to be useful for the development of novel DENV and CHIKV protease inhibitors.

Graphical abstract: Reaching beyond HIV/HCV: nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus

Back to tab navigation

Supplementary files

Article information


Submitted
21 Jul 2015
Accepted
05 Oct 2015
First published
05 Oct 2015

RSC Adv., 2015,5, 85938-85949
Article type
Paper
Author version available

Reaching beyond HIV/HCV: nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus

S. Bhakat, L. Delang, S. Kaptein, J. Neyts, P. Leyssen and V. Jayaprakash, RSC Adv., 2015, 5, 85938
DOI: 10.1039/C5RA14469H

Social activity

Search articles by author

Spotlight

Advertisements